Web-Base App To Improve Aromatase Inhibitor Adherence

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Breast Neoplasm Female
Interventions
BEHAVIORAL

Prompts to report symptoms via study app

Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.

BEHAVIORAL

Clinical Alerts

: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.

Trial Locations (2)

38104

West Cancer Center, MIDTOWN, 1588 Union Ave., Memphis

38138

West Cancer Center, EAST MEMPHIS, 7945 Wolf River Blvd, Memphis

All Listed Sponsors
collaborator

University of Tennessee West Cancer Center

OTHER

lead

University of Tennessee

OTHER

NCT02957526 - Web-Base App To Improve Aromatase Inhibitor Adherence | Biotech Hunter | Biotech Hunter